


AMENDMENTS TO THE CLAIMS

1-13. (Cancelled)

14. (Currently amended) A compound of formula III:



or a pharmaceutically acceptable salt thereof, wherein:

R⁶ and R⁹ are independently selected from H, R, OH, OR, SH, SR, NH₂, NHR, NRR', nitro, Me₃Sn and halo;

R and R' are independently selected from optionally substituted C₁₋₁₂ alkyl, C₃₋₂₀ heterocyclyl and C₅₋₂₀ aryl groups;

the compound being a dimer with each monomer being of formula (III), where the R⁸ groups of each monomer form together a dimer bridge having the formula -X-R"-X- linking the monomers, where R" is a C₃₋₁₂ alkylene group, which chain may be interrupted by one or more heteroatoms and/or aromatic rings, and each X is independently selected from O, S, or NH, and R⁷ is selected from H, R, OH, OR, SH, SR, NH₂, NHR, NRR', nitro, Me₃Sn and halo,

or any pair of adjacent groups from R⁸ to R⁹ together form a group

-O-(CH₂)_p-O-, where p is 1 or 2;

either R¹⁰ and R¹⁶ together form a double bond between N10 and C11, or R¹⁰ is H and R¹⁶ is OH, and ;

R¹⁵ is an optionally substituted C₅₋₂₀ aryl group,


wherein the ~~optionally optional~~ substituents are independently selected from the group consisting of C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₃₋₂₀ heterocyclyl, C₅₋₂₀ aryl, halo, hydroxyl, ether, -OR¹ wherein R¹ is a C₁₋₇ alkyl group or C₃₋₂₀ heterocyclyl group or C₅₋₁₀ aryl group, alkoxy, acetal -CH(OR¹)(OR²) wherein R¹ is as defined above and R² is independently a C₁₋₇ alkyl group or C₃₋₂₀ heterocyclyl group or C₅₋₁₀ aryl group or R¹ and R² together with the two oxygen atoms to which they are attached form a heterocyclic ring having from 4 to 8 ring atoms, hemiacetal -CH(OH)(OR¹) wherein R¹ is as defined above, ketal, hemiketal, oxo, thione, imino, formyl, acyl, carboxy, thiocarboxy, thiolocarboxy, imide acid -C(=NH)OH, hydroxamic acid -C(=NOH)OH, ester -C(=O)OR¹ wherein R¹ is as defined above, acyloxy, oxycarboxyloxy, amino, amido,

thioamido, acylamido, aminocarbonyloxy, ureido, guanidine, tetrazolyl, amidino, nitro, nitroso, azido, cyano, isocyano, cyanato, isocyanato, thiocyno, isothiocyano, sulfhydryl, thioether, disulfide, sulfine, sulfone, sulfonic acid $-S(=O)OH$, $-SO_2H$, sulfonic acid $-S(=O)_2OH$, $-SO_3H$, sulfinate, sulfonate, sulfinyloxy, sulfonyloxy, sulfate, sulfamyl, sulfonamide, sulfamino, sulfonamino, sulfinamino, phosphino, phosphor, phosphinyl, phosphono, ~~phosphono ester $-P(=O)(OR^{17})_2$ wherein R^{17} is $-H$ or C_{1-7} alkyl group or C_{3-20} heterocyclyl group or C_{5-20} aryl group,~~ phosphonoxy, ~~phosphonoxy ester $-PO(=O)(OR^{17})_2$ wherein R^{17} is as defined above,~~ phosphorous acid $-OP(OH)_2$, phosphate, phosphoramidite, or and phosphoramidate; and wherein heteroatoms of the heterocyclyl groups and the optional heteroatoms of the alkylene groups are independently selected from the group consisting of N, S, and O.


15. (Previously presented) A compound according to claim 14, wherein the dimer bridge has the formula $-O-(CH_2)_n-O-$ linking the monomers, where n is from 3 to 12.
16. (Previously presented) A compound according to claim 15, wherein n is from 3 to 7.
17. (Previously presented) A compound according to claim 14, wherein R^{10} and R^{16} together form a double bond between N10 and C11.
18. (Previously presented) A compound according to claim 14, wherein R^9 is H.
19. (Previously presented) A compound according to claim 14, wherein R^7 and R^8 are independently selected from H, OH, OR, SH, NH_2 , NHR, NRR' and halo.
20. (Canceled)
21. (Previously presented) A pharmaceutical composition containing a compound of claim 14, and a pharmaceutically acceptable carrier or diluent.
22. (Canceled)
23. (Currently amended) A method of treatment of chronic myeloid leukemia, comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound of claim 14.

24-29. (Cancelled)

30. (Currently amended) A method of ~~synthesizing~~ synthesising a compound of formula III:



comprising reacting a compound of formula I:



with a compound of formula z-R¹⁵ in a coupling reaction, wherein

R⁶ and R⁹ are independently selected from H, R, OH, OR, SH, SR, NH₂, NHR, NRR', nitro, Me₃Sn and halo;

R and R' are independently selected from optionally substituted

C₁₋₁₂ alkyl, C₃₋₂₀ heterocyclidyl and C₅₋₂₀ aryl groups;

R⁷ and R⁸ are independently selected from H, R, OH, OR, SH, SR, NH₂, NHR, NRR', nitro, Me₃Sn and halo,

or the compound is a dimer with each monomer being of formula (I), where the R⁷ groups or R⁸ groups of each monomers form together a dimer bridge having the formula -X-R"-X- linking the monomers, where R" is a C₃₋₁₂ alkylene group, which chain may be interrupted by one or more heteroatoms and/or aromatic rings, and each X is independently selected from O, S, or NH; or any pair of adjacent groups from R⁶ to R⁹ together form a group

-O-(CH₂)_p-O-, where p is 1 or 2;

R¹⁰ is a carbamate-based nitrogen protecting group;

R² is a labile leaving group;


R¹⁶ is either O-R¹¹, where R¹¹ is an oxygen protecting group, or OH, or R¹⁰ and R¹⁶ together form a double bond between N10 and C11;

z-R¹⁵ is any reactant suitable for a coupling reaction; and

R¹⁵ is an optionally substituted C₅₋₂₀ aryl group,

wherein the optionally optional substituents are independently selected from the group consisting of C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₃₋₂₀ heterocyclyl, C₅₋₂₀ aryl, halo, hydroxyl, ether -OR wherein R is a C₁₋₇ alkyl group or C₃₋₂₀ heterocyclyl group or C₅₋₁₀ aryl group, alkoxy, acetal -CH(OR¹)(OR²) wherein R¹ is as defined above and R² is independently a C₁₋₇ alkyl group or C₃₋₂₀ heterocyclyl group or C₅₋₁₀ aryl group or R¹ and R² together with the two oxygen atoms to which they are attached form a heterocyclic ring having from 4 to 8 ring atoms, hemiacetal -CH(OH)(OR¹) wherein R¹ is as defined above, ketal, hemiketal, oxo, thione, imino, formyl, acyl, carboxy, thiocarboxy, thiolocarboxy, imidic acid -C(=NH)OH, hydroxamic acid -C(=NOH)OH, ester -C(=O)OR¹ wherein R¹ is as defined above, acyloxy, oxycarboxyloxy, amino, amido, thioamido, acylamido, aminocarboxyloxy, ureido, guanidine, tetrazolyl, amidino, nitro, nitroso, azido, cyano, isocyano, cyanato, isocyanato, thiocyanato, isothiocyanato, sulfhydryl, thioether, disulfide, sulfine, sulfone, sulfonic acid -S(=O)OH, -SO₂H, sulfonic acid -S(=O)₂OH, -SO₃H, sulfinate, sulfonate, sulfinyloxy, sulfonyloxy, sulfate, sulfamyl, sulfonamide, sulfamino, sulfonamino, sulfinamino, phosphino, phosphor, phosphinyl, phosphono, phosphene ester -P(=O)(OR¹⁷)₂ wherein R¹⁷ is -H or C₁₋₇ alkyl group or C₃₋₂₀ heterocyclyl group or C₅₋₂₀ aryl group, phosphonoxy, phospheneoxy ester -PO(=O)(OR¹⁷)₂ wherein R¹⁷ is as defined above, phosphorous acid -OP(OH)₂, phosphate, phosphoramidite, or and phosphoramidate; and wherein heteroatoms of the heterocyclyl groups and the optional heteroatoms of the alkylene groups are independently selected from the group consisting of N, S, and O.

31. (Previously presented) A method according to claim 30, wherein the synthesis of said compound of formula III uses a palladium catalysed coupling step.
32. (Previously presented) A method according to claim 31, wherein the palladium catalyst is Pd(PPh₃)₄, Pd(OCOCH₃)₂, PdCl₂ or Pd(dba)₃.
33. (Previously presented) A method according to claim 31, wherein the coupling reaction is performed under microwave conditions.
34. (Previously presented) A method according to claim 31, wherein the palladium catalyst is solid supported.
35. (Currently amended) A compound of formula III



and salts and solvates thereof, wherein:

R^6 and R^9 are independently selected from H, R, OH, OR, SH, SR, NH_2 , NHR, NRR' , nitro, Me_3Sn and halo;

R and R' are independently selected from optionally substituted C_{1-12} alkyl, C_{3-20} heterocyclyl and C_{5-20} aryl groups;

the compound being a dimer with each monomer being of formula (III), where the R^8 groups of each monomer form together a dimer bridge having the formula $-X-R''-X-$ linking the monomers, where R'' is a C_{3-12} alkylene group, which chain may be interrupted by one or more heteroatoms and/or aromatic rings, and each X is independently selected from O, S, or NH, and R^7 is selected from H, R, OH, OR, SH, SR, NH_2 , NHR, NRR' , nitro, Me_3Sn and halo; or any pair of adjacent groups from R^6 to R^9 together form a group $-O-(CH_2)_p-O-$, where p is 1 or 2;

R^{10} is a carbamate-based nitrogen protecting group;


R^{16} is $-O-R^{11}$, where R^{11} is an oxygen protecting group or H; and

R^{15} is an optionally substituted C_{5-20} aryl group,


wherein the ~~optionally optional~~ substituents are independently selected from the group consisting of C_{1-12} alkyl, C_{3-12} cycloalkyl, C_{3-20} heterocyclyl, C_{5-20} aryl, halo, hydroxyl, ~~ether~~ $-OR$ wherein R is a C_{1-7} alkyl group or C_{3-20} heterocyclyl group or C_{5-10} aryl group, alkoxy, acetal $-CH(OR^1)(OR^2)$ wherein R^1 is as defined above and R^2 is independently a C_{1-7} alkyl group or C_{3-20} heterocyclyl group or C_{5-10} aryl group or R^1 and R^2 together with the two oxygen atoms to which they are attached form a heterocyclic ring having from 4 to 8 ring atoms, hemiacetal $-CH(OH)(OR^1)$ wherein R^1 is as defined above, ketal, hemiketal, oxo, thione, imino, formyl, acyl, carboxy, thiocarboxy, thiolocarboxy, imidic acid $-C(=NH)OH$, hydroxamic acid $-C(=NOH)OH$, ester $-C(=O)OR^1$ wherein R^1 is as defined above, acyloxy, oxycarboxyloxy, amino, amido, thioamido, acylamido, aminocarbonyloxy, ureido, guanidine, tetrazolyl, amidino, nitro, nitroso, azido, cyano, isocyano, cyanato, isocyanato, thiocyno, isothiocyno, sulfhydryl, thioether, disulfide, sulfine, sulfone, sulfonic acid $-S(=O)OH$, $-SO_2H$, sulfonic acid $-S(=O)_2OH$, $-SO_3H$, sulfinate, sulfonate, sulfinyloxy, sulfonyloxy, sulfate, sulfamyl, sulfonamide, sulfamino, sulfonamino, sulfinamino, phosphino, phosphor, phosphinyl, phosphono, phosphono-ester $-$

$P(=O)(OR^{17})_2$ wherein R^{17} is $-H$ or C_{1-7} alkyl group or C_{3-20} heterocyclyl group or C_{5-20} aryl group, phosphonoxy, phosphenoxy ester $-PO(=O)(OR^{17})_2$ wherein R^{17} is as defined above, phosphorous acid $-OP(OH)_2$, phosphate, phosphoramidite, or and phosphoramidate; and wherein heteroatoms of the heterocyclyl groups and the optional heteroatoms of the alkylene groups are independently selected from the group consisting of N, S, and O.

36. (Previously presented) A compound according to claim 35, wherein R^{10} is Troc.
37. (Previously presented) A compound according to claim 35, wherein R^{11} is a silyl oxygen protecting group or THP.
38. (Currently amended) A compound of formula I:



for use in the synthesis of a compound of formula III:



wherein:

R^6 and R^9 are independently selected from H, R, OH, OR, SH, SR, NH_2 , NHR, NRR' , nitro, Me_3Sn and halo;

R and R' are independently selected from optionally substituted

C_{1-12} alkyl, C_{3-20} heterocyclyl and C_{5-20} aryl groups;

R^7 is selected from H, R, OH, OR, SH, SR, NH_2 , NHR, NRR' , nitro, Me_3Sn and halo,

the compound of formula III being dimer with each monomer being of formula III, where the R⁸ groups of each monomer form together a dimer bridge having the formula -X-R''-X- linking the monomers, where R'' is a C₃₋₁₂ alkylene group, which chain may be interrupted by one or more heteroatoms and/or aromatic rings, and each X is independently selected from O, S, or NH; or any pair of adjacent groups from R⁶ to R⁹ together form a group -O-(CH₂)_p-O-, where p is 1 or 2;

R¹⁰ is a carbamate-based nitrogen protecting group, or either R¹⁰ and R¹⁶ together form a double bond between N10 and C11, or R¹⁰ is H and R¹⁶ is OH;

R¹¹ is an oxygen protecting group or H;

R² is a labile leaving group; and


R¹⁵ is an optionally substituted C₅₋₂₀ aryl group,

wherein the optionally optional substituents are independently selected from the group consisting of C₁₋₁₂ alkyl, C₃₋₁₂ cycloalkyl, C₃₋₂₀ heterocyclyl, C₅₋₂₀ aryl, halo, hydroxyl, ether -OR wherein R is a C₁₋₇ alkyl group or C₃₋₂₀ heterocyclyl group or C₅₋₁₀ aryl group, alkoxy, acetal -CH(OR¹)(OR²) wherein R¹ is as defined above and R² is independently a C₁₋₇ alkyl group or C₃₋₂₀ heterocyclyl group or C₅₋₁₀ aryl group or R¹ and R² together with the two oxygen atoms to which they are attached form a heterocyclic ring having from 4 to 8 ring atoms, hemiacetal -CH(OH)(OR¹) wherein R¹ is as defined above, ketal, hemiketal, oxo, thione, imino, formyl, acyl, carboxy, thiocarboxy, thiolocarboxy, imidic acid -C(=NH)OH, hydroxamic acid -C(=NOH)OH, ester -C(=O)OR¹ wherein R¹ is as defined above, acyloxy, oxycarboxyloxy, amino, amido, thioamido, acylamido, aminocarbonyloxy, ureido, guanidine, tetrazolyl, amidino, nitro, nitroso, azido, cyano, isocyano, cyanato, isocyanato, thiociano, isothiociano, sulfhydryl, thioether, disulfide, sulfine, sulfone, sulfonic acid -S(=O)OH, -SO₂H, sulfonic acid -S(=O)₂OH, -SO₃H, sulfinate, sulfonate, sulfinyloxy, sulfonyloxy, sulfate, sulfamyl, sulfonamide, sulfamino, sulfonamino, sulfinamino, phosphino, phosphor, phosphinyl, phosphono, phosphono ester -P(=O)(OR¹⁷)₂ wherein R¹⁷ is -H or C₁₋₇ alkyl group or C₃₋₂₀ heterocyclyl group or C₅₋₂₀ aryl group, phosphonoxy, phosphonoxy ester -PO(=O)(OR¹⁷)₂ wherein R¹⁷ is as defined above, phosphorous acid -OP(OH)₂, phosphate, phosphoramidite, or and phosphoramidate; and wherein heteroatoms of the heterocyclyl groups and the optional heteroatoms of the alkylene groups are independently selected from the group consisting of N, S, and O.

39. (Previously presented) A compound according to claim 19, wherein R⁷ is OR.

40. (Previously presented) A compound according to claim 19, wherein R⁷ is OMe.

41. (Previously presented) A compound according to claims 14 wherein R^{15} is a C_{5-20} aryl group optionally substituted with a substituent selected from the group consisting of R, OH, OR, NH_2 , NHR, NRR' , CN, $C(=O)H$, $C(=O)OH$ and halo.
42. (Previously presented) A compound according to claim 14, wherein R^{15} is a C_{5-20} aryl group substituted by OR.
43. (Previously presented) A compound according to claim 14, wherein R^{15} is a C_{5-20} aryl group substituted by OMe.
44. (Previously presented) A compound according to claim 14, wherein R^8 is H, R^7 is OMe, X is O, R'' is $(CH_2)_3$, R^9 is H, R^{10} and R^{16} together form a double bond between N10 and C11, and R^{15} is para-methoxyphenyl.
45. (New) The compound of claim 14, wherein R'' is a C_{3-12} alkylene group interrupted by one or more heteroatoms, wherein the one or more heteroatoms are independently selected from the group consisting of O, S, and N.
46. (New) A compound of the following formula:



or a pharmaceutically acceptable salt thereof.

47. (New) The compound of claim 14, wherein R and R' are unsubstituted.
48. (New) The compound of claim 14, wherein R^{15} is an unsubstituted C_{5-20} aryl group.
49. (New) The compound of claim 14, wherein R^{15} is a singly substituted C_{5-20} aryl group.